JMP Sees Big Gains in Rapport Therapeutics, Inc. (RAPP) After Focal Epilepsy Study Success

Rapport Therapeutics, Inc. (NASDAQ:RAPP) is among the best fast money stocks to buy now. Analysts at JMP Securities have reaffirmed their ‘Market Outperform’ rating on Rapport Therapeutics, Inc. (NASDAQ:RAPP) with a price target of $77, implying a potential surge of about 174%. This announcement follows the publication of “stellar results” from the Phase 2a trial for RAP-219 in refractory focal epilepsy.

Keeping in view the year-to-date returns posted by Rapport Therapeutics, Inc. (NASDAQ:RAPP), the company outperformed the market by an impressive 45%. What’s even more interesting about the company is its recent data, which is defined by a large market of 1.8 million patients in the U.S., with 40% of them continuing to be treatment resistant.

During the presentation at TD Cowen’s 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit, the leadership expressed enthusiasm about its RAP-219, which they view as a multibillion-dollar market opportunity. As stated by the CEO, Abraham Ceesay,

And that’s really defined by a novel MOA with RAP-219; two, efficacy that we think is really best-in-class from what we’ve seen from our proof-of-concept study, a drug that’s generally well tolerated and consistent with precision biology.

Rapport Therapeutics, Inc. (NASDAQ:RAPP), headquartered in Boston, Massachusetts, is a clinical-stage biopharmaceutical company that develops medicines for individuals living with central nervous system disorders. Incorporated in 2022, the company is committed to developing therapies with enhanced efficacy.

While we acknowledge the potential of RAPP as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.